• Earlier this month, Pharvaris announced that the FDA accepted its New Drug Application for deucrictibant immediate-release 20 mg capsules for on-demand treatment of Hereditary Angioedema attacks, supported by Phase 3 RAPIDe-3 data covering more than 1,300 treated attacks.
• The filing showcases an oral bradykinin B2 receptor antagonist that achieved rapid symptom relief, End of Progression, and complete attack resolution with statistical significance across all primary and secondary endpoints in a pivotal trial.
• Next, we’ll examine how deucrictibant’s Phase 3 success and NDA acceptance shape Pharvaris’ investment narrative in hereditary angioedema therapeutics.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

What Is Pharvaris' Investment Narrative?

For Pharvaris, being a shareholder largely means believing in deucrictibant as a foundational HAE franchise, not just a one-off product. The FDA’s acceptance of the NDA for the on-demand capsule locks in a clear regulatory timeline and strengthens the near-term catalyst path, alongside upcoming CHAPTER-3 prophylaxis data. It also raises the stakes: with no revenue, persistent annual losses above €100 million, and ongoing equity dilution, the business is heavily dependent on successful approval and eventual uptake of its oral therapies. The stock’s strong 1-year return and sizeable discount to pre-news fair value estimates suggest the NDA milestone was at least partly anticipated, so the event may not radically reset expectations, but it does sharpen the focus on regulatory, execution, and financing risks from here.

However, one risk in particular could matter far more than the NDA outcome itself. Despite retreating, Pharvaris' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Simply Wall St Community members currently contribute 1 fair value view clustered around US$47.38, while the recent NDA acceptance for deucrictibant puts renewed attention on regulatory timelines and Pharvaris’ ongoing cash burn, encouraging you to weigh multiple angles on how execution risk could influence future outcomes.

Explore another fair value estimate on Pharvaris - why the stock might be worth just $47.38!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pharvaris research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Pharvaris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharvaris' overall financial health at a glance.

No Opportunity In Pharvaris?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.